Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion–Positive Non–Small Cell Lung Cancer The content is solely the responsibility of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results